Speaker:
Luis Carrillo, MD
At the conclusion of this activity, participants should be able to:
* Become familiar with new immunotherapies used in the treatment of hematolymphoid neoplasms
* Understand the approaches to minimal residual disease in plasma cell myeloma
* Recognize strategies for optimizing flow cytometric results in the era of immunotherapy
Pathology Grand Rounds